PREMARKET ALERT: Anadys Pharmaceuticals (ANDS)

Posted in General 
July 31st, 2009

Anadys Pharmaceuticals Inc. (Nasdaq: ANDS) are up 50 percent to $2.72 on premarket trading of more than 1,500 shares as of 7:30 a.m. Eastern. The FDA has given the company clearance of its Phase II protocol to study its hepatitis C drug candidate ANA598, which has faced safety concerns after patients dropped out of a previous study with a rash. Patient dosing in a 90-patient trial is expected to star within the next several weeks. The company also posted a narrower-than-expected quarterly loss of 21 cents a share, vs. analyst expectations of a 28-cent loss. — Mike Tarsala

Comments are closed